Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $10.0200 (4.54%) ($10.0200 - $10.0200) on Sat. Mar. 19, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.49% (three month average) | RSI | 50 | Latest Price | $10.0200(4.54%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.9% a day on average for past five trading days. | Weekly Trend | TGTX declines -4.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting TGTX price | TGTX will decline at least -3.745% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.745% (StdDev 7.49%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-6.98(-169.66%) | 5 Day Moving Average | $8.83(13.48%) | 10 Day Moving Average | $8.84(13.35%) | 20 Day Moving Average | $9.3(7.74%) | To recent high | -51% | To recent low | 28.5% | Market Cap | $N/A | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |